Pliant Therapeutics has scrapped its Phase IIb Beacon-IPF trial for bexotegrast in idiopathic pulmonary fibrosis (IPF), after ...

Pliant Therapeutics (NASDAQ:PLRX – Free Report) had its price objective lowered by Citigroup from $4.00 to $1.50 in a report ...

The company’s stock price has dropped to around $1.38 per share after its IPF therapy trial was stopped for safety.

Pliant Therapeutics ends its Phase 2b IPF trial for bexotegrast, prompting a Needham downgrade to Hold due to limited ...

Fintel reports that on March 4, 2025, Needham downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from Buy to ...

The trial, dubbed BEACON-IPF, was assessing the biotech’s lead candidate, an oral small molecule called bexotegrast. The ...

Fintel reports that on March 3, 2025, Leerink Partners downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from ...

Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the ...

Discontinuation of BEACON-IPF following DSMB and outside expert panel recommendationSOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE ...

Pliant Therapeutics discontinued its BEACON-IPF trial for bexotegrast due to safety concerns but observed early efficacy. The ...

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) was downgraded by equities research analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating in a research note issued on Monday, ...

Citi lowered the firm’s price target on Pliant Therapeutics (PLRX) to $1.50 from $4 and keeps a Neutral rating on the shares. The company ...